Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Tomorrow Morning on NPR: BIO, ACLU Discuss Gene Patenting

You can listen from your desk at http://www.wbur.org/listen. Callers will have the opportunity to ask questions after the first 20 minutes. If you’re interested in the topic, you can find background material on gene patenting at http://bio.org/ip/genepat/ and our amicus brief in the ACLU lawsuit is posted at http://bio.org/ip/amicus/documents/BIOAmicusBriefACLU-Myriad12-09.pdf.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

IP Professors: 12-Year Data Exclusivity a Win-Win for Patient Access & Biotech Innovation

David E. Adelman of the University of Texas School of Law and Christopher M. Holman of the University of Missouri – Kansas City School of Law recently published analysis on the “sideshow” of the data exclusivity debate in Washington.

Adelman and Holman use a cost-benefit analysis that incorporates the most important legal precedents and case law today in concluding that “policymakers should focus on mitigating the systematic barriers to entry that pose much greater and longer-term obstacles to lower-cost biotech drugs.” Specifically, the draft paper provides solid analysis of the need for 12-year data exclusivity, which the authors describe as a perfect balance between providing access to important medicines to patients, and creating the incentives needed for investors and companies to prepare (and survive) the regulatory approval process for follow-on biologics.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Technology Transfer Symposium Presentations Published

You can access all the presentations from the Technology Transfer Symposium, held in October 2009 at the BIO Investor Forum, by visiting http://bio.org/ip/techtransfer/. For more information, you can contact Margarita Noriega, Coordinator of Bioethics & IP Policy, at mnoriega@bio.org.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

Director’s Forum: David Kappos’ Public Blog

The Director of the U.S. Patent & Trademark Office posted his first blog post today. You can visit the blog at http://www.uspto.gov/blog/.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

BIO Survey on Technology Transfer Shows Complexity of University-Industry Relationships

I sat down with Cartier Esham, Director, Emerging Company Health and Regulatory Affairs at BIO, to discuss BIO’s new survey on licensing trends between universities and companies, part of a larger process of technology transfer. BIO will release the survey at this year’s BIO Investor Forum Technology Transfer Symposium, October 28, 2009. You can learn more about by visiting www.bio.org/ip/techtransfer.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,